Related Experiment Video

Updated: Feb 28, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.2K

Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)

Caroline M Robb1, Jacob I Contreras, Smit Kour

  • 1Eppley Institute for Research in Cancer and Allied Diseases, Omaha, Nebraska 68022, USA. anatarajan@unmc.edu sandeep.rana@unmc.edu.

Chemical Communications (Cambridge, England)
|June 22, 2017
PubMed

Insights

Researchers developed a novel PROTAC molecule to selectively degrade Cyclin-dependent kinase 9 (CDK9), a protein implicated in various cancers. This targeted approach offers a new strategy for cancer therapy by specifically eliminating CDK9 without affecting other related proteins.

Area of Science:

  • Molecular Biology
  • Oncology
  • Drug Discovery

Background:

  • Cyclin-dependent kinase 9 (CDK9) is crucial for transcriptional elongation and implicated in multiple cancers, including pancreatic, prostate, and breast cancer.
  • Targeting CDK9 presents a potential therapeutic strategy for malignancies, but selective inhibition or degradation remains a challenge.

Purpose of the Study:

  • To develop and characterize a novel heterobifunctional small molecule proteolysis targeting chimera (PROTAC) for the selective degradation of CDK9.
  • To demonstrate the efficacy and selectivity of the developed PROTAC in a cellular model.

Main Methods:

  • Design and synthesis of a heterobifunctional PROTAC molecule.
  • Utilizing cereblon (CRBN) as an E3 ligase for targeted protein degradation.
  • Assessing CDK9 degradation in HCT116 cancer cells using cellular assays.

Main Results:

  • Successful development of a PROTAC that induces cereblon (CRBN)-mediated proteasomal degradation of CDK9.
  • Demonstrated selective degradation of CDK9 in HCT116 cells.
  • Confirmed that the PROTAC spares other members of the cyclin-dependent kinase (CDK) family.

Conclusions:

  • This study reports the first PROTAC capable of selectively degrading CDK9.
  • The developed PROTAC represents a promising new chemical modality for targeting CDK9 in cancer therapy.
  • Further investigation into this PROTAC's therapeutic potential in various malignancies is warranted.

More Related Videos

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

4.6K
Studying Proteolysis of Cyclin B at the Single Cell Level in Whole Cell Populations10:54

Studying Proteolysis of Cyclin B at the Single Cell Level in Whole Cell Populations

Published on: September 17, 2012

11.1K

Related Concept Videos

Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Separation of Sister Chromatids02:17

Separation of Sister Chromatids

At the transition from prophase to metaphase, there is a reduction in cohesion along the chromosomal arms, resulting in the resolution of sister chromatids. However, residual cohesin connections remain to hold the sister chromatids together until the transition from metaphase to anaphase. The residual connection prevents any premature separation of sister chromatids, blocking the risks of aneuploidy within the daughter cells.
At the onset of anaphase, separase, a proteolytic enzyme, is...
4.6K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.9K